Journal: Oncology Letters
Article Title: Comprehensive treatment for two patients with small cell neuroendocrine carcinoma of the liver: A case report and literature review
doi: 10.3892/ol.2026.15544
Figure Lengend Snippet: Case 2: Pathology of S5 hepatocellular carcinoma: High magnification reveals tumor cells that are polygonal in shape, with round nuclei, prominent nucleoli and cytoplasm exhibiting a finely granular appearance. (A) H&E (magnification, ×100; scale bar, 73 µm). Immunohistochemical results: (B) Arginase-1 (+), with arrows indicating cytoplasmic positivity in tumor cells; (C) hepatocyte paraffin 1 (+), with arrows indicating cytoplasmic granular positivity; (D) Ki-67 (~15%+ in active area), with arrows indicating nuclear positivity in proliferating tumor cells; (E) glutamine synthetase (+), with arrows indicating cytoplasmic positivity in a map-like distribution pattern; (F) glypican-3 (focally +), with arrows indicating focal cytoplasmic and membranous positivity; (G) heat shock protein 70 (focally +), with arrows indicating focal nuclear and cytoplasmic positivity; and (H) CD34 (showing diffuse capillary distribution), with arrows highlighting the characteristic sinusoidal endothelial staining pattern (magnification, ×40; scale bar, 221 µm).
Article Snippet: The following primary antibodies were used: Pan-cytokeratin (CKpan; cat. no. ZM-0069), vimentin (cat. no. ZM-0260), CgA (cat. no. ZA-0507), Syn (cat. no. ZA-0569), cluster of differentiation 56 (CD56; cat. no. ZM-0427), TTF-1 (cat. no. ZM-0270), arginase-1 (cat. no. ZA-0641), HepPar-1 (cat. no. ZM-0133), P53 (cat. no. ZM-0408), Ki-67 (cat. no. ZM-0166), CD34 (cat. no. ZM-0046), CK19 (cat. no. ZM-0074), alpha-fetoprotein (AFP; cat. no. ZM-0008), CK7 (cat. no. ZM-0071), CK20 (cat. no. ZM-0072), Villin (cat. no. ZM-0441), caudal type homeobox 2 (CDX2; cat. no. ZA-0520), MutL homolog 1 (MLH1; cat. no. ZA-0544), MutS homolog 2 (MSH2; cat. no. ZA-0542), MSH6 (cat. no. ZA-0546), postmeiotic segregation increased 2 (PMS2; cat. no. ZA-0548), glutamine synthetase (cat. no. ZA-0645), glypican-3 (cat. no. ZM-0446), heat shock protein 70 (HSP70; cat. no. ZA-0580; all ready-to-use; from OriGene Technologies, Inc.), and programmed cell death ligand 1 (PD-L1; cat. no. M3653; dilution 1:50; Dako; Agilent Technologies, Inc.).
Techniques: Immunohistochemical staining, Staining
Millipore is a verified supplier 
